公司董事会对李峰先生在任职期间为公司发展所做出的贡献表示衷心感谢！ 证券代码：301333 证券简称：诺思格 公告编号：2024-077 诺思格（北京）医药科技股份有限公司 关于独立董事辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 近日，诺思格（北京）医药科技股份有限公司（以下简称"公司"）董事会 收到公司独立董事李峰先生的书面辞职申请，李峰先生因个人原因辞去公司第五 届董事会独立董事及董事会审计委员会主任委员、薪酬与考核委员会委员职务。 辞职后，李峰先生将不再担任公司任何职务。 李峰先生的辞职将导致公司独立董事人数比例低于公司董事总数的三分之 一，根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》及《公司章程》等有关规定，李峰先生 的辞职申请将在公司股东大会补选出新任独立董事后生效。在新任独立董事就任 前，李峰先生将按照相关法律法规及《公司章程》的规定，继续履行独立董事及 其在董事会相关专门委员会中的职责。 截至本公告披露日，李峰先生未持有公司股份，不存在应当履行而未履行的 承诺事项。 ...

关于高级管理人员变动的公告 证券代码：301333 证券简称：诺思格 公告编号：2024-076 诺思格（北京）医药科技股份有限公司 特此公告。 诺思格（北京）医药科技股份有限公司董事会 2024 年 11 月 15 日 1 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 近日，诺思格（北京）医药科技股份有限公司（以下简称"公司"）董事会 收到公司首席科学官、副总经理 CHEN GANG（陈刚）先生提交的关于辞任公司 副总经理的申请，CHEN GANG（陈刚）先生因工作重心调整申请辞去公司副总 经理职务，其申请自提交董事会之日起生效。CHEN GANG（陈刚）先生仍将继 续担任公司首席科学官、子公司南京艾科曼信息技术有限公司执行董事、美国子 公司 R&G US Inc.董事职务，并更加专注于公司生物医药科学研发事务及加速推 动公司海外业务开展。 截至本公告披露日，CHEN GANG（陈刚）先生直接及间接合计持有公司股 份 374,400 股。CHEN GANG（陈刚）先生不存在应当履行而未履行的承诺事项， 在辞任后将继续遵守减持相关法律法规及所做出的相关承诺。 ...

特别提示： 1、持有本公司股份4,800,000股（占本公司总股本比例5.0452%）的股东和 谐成长二期（义乌）投资中心（有限合伙）（以下简称"和谐成长二期"）与持有 本公司股份2,155,200股（占本公司总股本比例2.2653%）的股东珠海和谐康健投 资基金（有限合伙）（以下简称"和谐康健"）计划以大宗交易方式、集中竞价交 易方式进行股份减持。 2、和谐成长二期与和谐康健已向中国证券投资基金业协会（以下简称"基 金业协会"）申请适用《上市公司创业投资基金股东减持股份的特别规定》（以 下简称"《创投减持特别规定》"）和《深圳证券交易所上市公司创业投资基金 股东减持股份实施细则》（以下简称"《创投减持实施细则》"），并已通过基金 业协会备案。 证券代码：301333 证券简称：诺思格 公告编号：2024-075 诺思格（北京）医药科技股份有限公司 关于持股 5%以上股东及其一致行动人减持股份预披 露公告 本公司股东和谐成长二期（义乌）投资中心（有限合伙）、珠海 和谐康健投资基金（有限合伙）保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与 ...

Investment Rating - The report maintains a "Recommended" rating for the company [1][3]. Core Views - The company achieved a revenue of 562 million yuan in the first three quarters of 2024, representing a year-on-year growth of 7.10%. However, the net profit attributable to the parent company decreased by 32.93% to 84 million yuan [1]. - The company signed new contracts worth 976 million yuan in 2023, a significant increase of 20% year-on-year, primarily from orders from pharmaceutical and biotechnology companies in China [2]. - The profit decline is largely attributed to the amortization of expenses related to the stock incentive plan. Excluding this impact, the adjusted net profit would have shown a smaller decline of 4.40% year-on-year [2]. - The favorable market environment for the biopharmaceutical industry is expected to continue, supported by government policies and investment funds [2]. Financial Summary - For 2024, the company is projected to have a net profit of 121 million yuan, a decrease of 25.4% year-on-year, with an EPS of 1.26 yuan. The projections for 2025 and 2026 are 170 million yuan and 191 million yuan, respectively, with corresponding EPS of 1.76 yuan and 1.97 yuan [3][6]. - The total revenue is expected to grow from 721 million yuan in 2023 to 789 million yuan in 2024, with a year-on-year growth rate of 9.3% [6]. - The company's total market value is currently estimated at 64.13 billion yuan, with a target price set at 80 yuan based on a PE ratio of 45 for 2025 [4][3].

证券代码：301333 证券简称：诺思格 公告编号：2024-074 诺思格（北京）医药科技股份有限公司 关于股份回购进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 诺思格（北京）医药科技股份有限公司（以下简称"公司"）于 2024 年 7 月 1 日召开第五届董事会第二次会议，审议通过《关于回购公司股份方案的议案》。 公司拟使用自有资金以集中竞价交易方式回购公司股份，用于员工持股计划或股 权激励。本次回购的资金总额不低于 5,000 万元（含本数）且不超过 8,000 万元 （含本数），回购价格不超过 58.00 元/股（含本数）。具体回购股份的数量以回 购实施完毕时实际回购的股份数量为准。本次回购期限自董事会审议通过之日起 12 个月内。 由于公司 2023 年度权益分派已实施完毕，根据相关规定，自除权除息日(即 2024 年 7 月 5 日)起，回购价格不超过人民币 58.00 元/股（含本数）调整为不超 过人民币 57.80 元/股（含本数）。以上具体内容详见公司 2024 年 7 月 6 日在巨 潮资讯网（http://www.cninf ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 562 million yuan in the first three quarters of 2024, representing a year-on-year growth of 7.10%. However, the net profit attributable to shareholders decreased by 32.93% to 84 million yuan, primarily due to the impact of share-based payment expenses. Excluding this impact, the adjusted net profit was 120 million yuan, a decline of 4.40% [2][4] - The company is actively promoting an employee stock ownership plan, which aims to enhance the stability of management and core technical personnel, supporting long-term development [3] - The company provides comprehensive clinical trial operation services and specialized services, with significant growth in the SMO and DM/ST business segments. The SMO segment achieved a revenue of 990 million yuan, growing by 12.24%, while the DM/ST segment grew by 42.14% [4] Financial Summary - For 2024, the company is projected to achieve a revenue of 804 million yuan, with a year-on-year growth of 11.4%. The net profit attributable to shareholders is expected to be 137 million yuan, reflecting a decline of 15.9% [5] - The gross margin is forecasted to be 39.9%, and the net margin is expected to be 17.0% for 2024 [5] - The earnings per share (EPS) for 2024 is estimated at 1.42 yuan, with a price-to-earnings (P/E) ratio of 41.0 times [5]

Revenue and Profit - Revenue for Q3 2024 reached ¥182,933,748.78, an increase of 12.42% year-over-year, while year-to-date revenue totaled ¥561,924,953.41, up 7.10% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥25,906,667.14, a decrease of 35.04% year-over-year, with year-to-date net profit at ¥84,417,173.32, down 32.93%[2] - Basic earnings per share for Q3 2024 was ¥0.27, reflecting a decline of 35.71% year-over-year, while year-to-date basic earnings per share was ¥0.88, down 32.82%[2] - Total operating revenue for Q3 2024 reached ¥561,924,953.41, an increase of 7.6% compared to ¥524,666,803.13 in the same period last year[24] - Net profit for Q3 2024 was ¥85,896,155.95, a decrease of 31.9% from ¥126,307,007.23 in Q3 2023[25] - The total comprehensive income attributable to the parent company was CNY 84.10 million, a decrease from CNY 125.73 million in the previous year, representing a decline of about 33.1%[26] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥2,298,881,931.34, representing a 10.85% increase from the end of the previous year[2] - The company's total assets increased to ¥2,298,881,931.34, compared to ¥2,073,816,068.79 at the end of the previous year, marking a growth of 10.8%[24] - Current liabilities rose to ¥444,746,001.68, up from ¥314,357,004.32, representing an increase of 41.4%[24] - The company’s total equity attributable to shareholders increased by 2.12% year-over-year, reaching ¥1,785,493,360.90[2] - The total equity attributable to shareholders reached ¥1,785,493,360.90, up from ¥1,748,411,556.50, reflecting an increase of 2.1%[24] Cash Flow - The company reported a net cash flow from operating activities of ¥105,405,875.78 year-to-date, which is a decrease of 18.40% compared to the same period last year[2] - The net cash flow from investing activities decreased by 42.03% to -380,303,828.54 RMB compared to the previous year, primarily due to reduced cash management product investments[11] - The net cash flow from financing activities increased by 153.07% to -37,999,306.16 RMB, mainly due to increased dividend payments and bank acceptance bill guarantees[11] - The net increase in cash and cash equivalents was -314,278,679.33 RMB, down 41.75% year-on-year, attributed to decreased cash management product investments[11] - The cash and cash equivalents at the end of the period were CNY 677.20 million, down from CNY 981.64 million at the end of the previous year, indicating a decrease of approximately 30.9%[29] Shareholder Information - The total number of common shareholders at the end of the reporting period was 5,836, with the largest shareholder, ACE UNION HOLDING LIMITED, holding 28.68% of shares[12] - The second-largest shareholder, Ningbo Kaihong Venture Investment Partnership, held 12.23% of shares, totaling 11,736,000 shares[12] - The company’s repurchase account held 1,442,000 unrestricted shares, accounting for 1.50% of the total share capital at the end of the reporting period[14] - As of September 30, 2024, the company has repurchased a total of 1,442,000 shares, accounting for 1.50% of the total share capital of 96,000,000 shares, with a total transaction amount of 56,062,734.00 RMB[19] - The company plans to repurchase shares with a total amount not less than 50 million RMB and not exceeding 80 million RMB, with a repurchase price capped at 57.80 RMB per share[18] Expenses and Costs - Total operating costs amounted to ¥479,667,281.05, up from ¥409,051,992.42, reflecting a year-over-year increase of 17.2%[25] - Management expenses for the year-to-date period reached ¥85,287,977.23, an increase of 86.91% year-over-year, primarily due to stock incentive plan amortization[10] - Research and development expenses for the quarter were ¥42,212,732.60, compared to ¥39,093,474.01, an increase of 5.4%[25] Acquisitions and Investments - The company acquired 100% equity of Shanghai Hengling Pharmaceutical Technology Co., Ltd. in January 2024[15] - In March 2024, the company established NuoSiGe (Nanjing) Pharmaceutical Technology Co., Ltd. with a registered capital of 2 million RMB, holding 100%[15] - The company established an industry fund in collaboration with CICC Capital, which has completed registration and obtained the business license[17] Legal Matters - The company is involved in a legal dispute regarding a contract dispute with its actual controller and a subsidiary, with ongoing litigation updates[18] Other Financial Metrics - The company experienced a significant increase in goodwill, which rose by 102,005.36% due to the acquisition of a subsidiary[7] - The company reported a 384.23% increase in fair value changes in financial assets, totaling ¥9,443,052.07, attributed to an increase in the amount of financial products not yet matured[10] - The company’s cash and cash equivalents decreased by 30.31% to ¥690,986,044.89, primarily due to an increase in the balance of bank cash management products not yet matured[7] - The company’s accounts receivable increased from 89,996,806.71 RMB to 100,431,414.26 RMB during the reporting period[22] - The company’s deferred tax assets increased to ¥12,574,972.73 from ¥7,620,348.72, a growth of 65.5%[24] - The company incurred cash outflows from financing activities amounting to CNY 105.71 million, compared to CNY 15.02 million in the previous year, indicating a significant increase in cash outflows[28]

第四届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：301333 证券简称：诺思格 公告编号：2024-073 诺思格（北京）医药科技股份有限公司 一、监事会会议召开情况 （一）审议通过《关于<2024年第三季度报告全文>的议案》 诺思格（北京）医药科技股份有限公司（以下简称"公司"）第四届监事会 第五次会议于2024年10月29日在公司会议室以现场结合通讯方式召开。会议通知 已于2024年10月24日以电子邮件、专人送达等方式送达全体监事。本次会议应出 席监事3人，实际出席监事3人。会议由监事会主席关虹女士主持。会议召开符合 有关法律、法规、规章和《诺思格（北京）医药科技股份有限公司章程》的规定。 二、监事会会议审议情况 表决情况：3票同意；0票弃权；0票反对。 经审议，监事会认为：董事会编制和审议公司2024年第三季度报告的程序符 合法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了上 市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。公司董事 会审计委员会已审议通过该议案。 具体内容详见公 ...

第五届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：301333 证券简称：诺思格 公告编号：2024-072 诺思格（北京）医药科技股份有限公司 三、备查文件 1、《第五届董事会第六次会议决议》； 2、《第五届董事会审计委员会2024年第三次会议决议》。 特此公告。 一、董事会会议召开情况 诺思格（北京）医药科技股份有限公司（以下简称"公司"）第五届董事会 第六次会议（以下简称"本次会议"）于2024年10月29日在公司会议室以现场结 合通讯方式召开。会议通知已于2024年10月24日以电子邮件、专人送达等方式送 达全体董事。本次会议应出席董事9人，实际出席董事9人。会议由董事长武杰先 生主持，会议的召开符合有关法律、法规、规章和《诺思格（北京）医药科技股 份有限公司章程》（以下简称《公司章程》）的规定。 二、董事会会议审议情况 （一）审议通过《关于<2024年第三季度报告全文>的议案》 表决情况：9票同意；0票弃权；0票反对。 经审议，董事会认为：公司《2024年第三季度报告》的议案符合法律法规、 中国证监会和深圳证券 ...

Investment Rating - The report initiates coverage on the company with a "Buy" rating, estimating a reasonable PE of 50x for 2024, corresponding to a market cap of 7.6 billion CNY [2] Core Views - The company is a leading clinical CRO in China, benefiting from policy support for innovative drug development and the increasing demand for efficient, cost-effective clinical research services [1] - The company's full-chain business integration and high-quality services are expected to drive sustainable growth, supported by its diversified service offerings and strong management team [1] - The clinical CRO industry is poised for growth due to favorable policies, rising R&D investments, and the increasing complexity of drug development, which drives demand for specialized CRO services [1][2] Industry Overview - The global pharmaceutical market is projected to grow from 14,950 billion USD in 2022 to 20,908 billion USD by 2030, with China's market expected to expand from 15,541 billion CNY to 26,245 billion CNY over the same period [33][34] - The global CRO market is forecasted to grow from 821.1 billion USD in 2023 to 1,064.5 billion USD by 2026, with China's CRO market expected to reach 597.9 billion CNY by 2026, driven by increasing R&D expenditures and policy support [42][43] - The average cost of developing a new drug has risen from 1.3 billion USD in 2013 to 2.01 billion USD in 2021, while the return on investment has declined, highlighting the need for CROs to improve efficiency and reduce costs [45][46] Company Strengths - The company offers a comprehensive range of clinical CRO services, including clinical trial operations (CO), site management (SMO), biostatistics, and clinical pharmacology, with a strong focus on innovation and quality [1][50] - The company has a robust management and scientific team with extensive international experience, including former FDA experts, enhancing its ability to provide strategic and regulatory guidance [24][25] - The company has implemented equity incentive plans to motivate core employees, with performance targets set for 2023-2025, aiming for a 20%, 44%, and 72.8% growth in non-GAAP net profit compared to 2022 [1][25] Financial Performance - The company's revenue grew from 326 million CNY in 2018 to 721 million CNY in 2023, with a CAGR of 17.2%, while net profit increased from 48 million CNY to 163 million CNY over the same period, with a CAGR of 27.4% [26][27] - The company's gross margin and net margin have remained stable, with CO services contributing 49% of revenue in 2023, and SMO services showing strong growth with a 21% YoY increase in 2023 [28][52] - The company's new contract value reached 976 million CNY in 2023, a 20.01% increase YoY, driven by demand from domestic pharmaceutical and biotech companies [30][31] Future Outlook - The company is expected to benefit from the increasing complexity of drug development and the growing demand for specialized CRO services, with projected revenue of 799 million CNY, 920 million CNY, and 1,073 million CNY for 2024-2026, respectively [2][6] - The company plans to expand its overseas business, enhance operational efficiency, and strengthen its industrial foundation, supported by the synergistic development of its six major business segments [2][20] - The company's high-margin emerging businesses, such as clinical pharmacology and consulting services, are expected to drive future growth, with a focus on optimizing its business structure and creating new profit growth points [58][59]